How should rheumatologists and pharmacists make clinical decisions when choosing between biosimilars and their reference biologic agents in the setting of RA, AS, psoriatic arthritis and related conditions?

How should rheumatologists and pharmacists make clinical decisions when choosing between biosimilars and their reference biologic agents in the setting of RA, AS, psoriatic arthritis and related conditions?

Based on the available data for clinical equivalency and switching, can you discuss how rheumatologists and pharmacists should make clinical decisions when choosing between biosimilars and their reference biologic agents in the setting of RA, AS, psoriatic arthritis and related conditions?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Stanley Cohen, MD

Stanley Cohen, MD

Clinical Professor
Department of Internal Medicine
UT Southwestern Medical Center
Co-Director of the Division of Rheumatology
Presbyterian Hospital
Dallas, Texas